外科理论与实践 ›› 2025, Vol. 30 ›› Issue (04): 295-301.doi: 10.16139/j.1007-9610.2025.04.02
收稿日期:2024-10-16
出版日期:2025-07-25
发布日期:2025-10-23
通讯作者:
朱建伟,E-mail: jwzhumd@aliyun.com
YUAN Xiaobing1, ZHU Jianwei2(
)
Received:2024-10-16
Online:2025-07-25
Published:2025-10-23
摘要:
目的:以生物信息学研究为基础,探讨miR-4674表达变化对BGC-823胃癌细胞系生物学特征的影响。方法:通过生物信息学分析,得到与胃癌关系密切的研究靶点miR-4674,构建miR-4674模拟物(mimic)、抑制物(inhibitor)以及相关阴性对照(NC)转染至BGC-823细胞系。应用逆转录聚合酶链式反应(RT-PCR)方法检测BGC-823细胞中miR-4674的表达变化。应用噻唑蓝(MTT)法检测细胞增殖能力。应用Transwell培养体系检测细胞迁移能力,应用TUNEL检测细胞的凋亡情况。结果:与空白对照组以及转染NC的细胞比较,转染miR-4674 mimic的细胞中miR-4674表达水平明显升高,细胞的增殖与迁移能力均明显升高(P<0.05),而转染miR-4674 inhibitor的细胞中miR-4674表达水平明显降低,细胞的增殖与迁移能力均明显下降(P<0.05)。TUNEL检测结果显示,各组均未见到凋亡细胞。结论:在BGC-823胃癌细胞系抑制miR-4674表达降低其恶性程度,在BGC-823胃癌细胞系过表达miR-4674则促进其恶性程度,miR-4674可能是胃癌干预的治疗靶点,为胃癌的治疗提供了新的策略。
中图分类号:
袁小兵, 朱建伟. miR-4674表达变化对BGC-823胃癌细胞系生物学特征的影响[J]. 外科理论与实践, 2025, 30(04): 295-301.
YUAN Xiaobing, ZHU Jianwei. Impact of miR-4674 expression changes on the biological characteristics of BGC-823 gastric cancer cell line[J]. Journal of Surgery Concepts & Practice, 2025, 30(04): 295-301.
| [1] | PAWLUCZUK E, ŁUKASZEWICZ-ZAJĄC M, MROCZKO B. The comprehensive analysis of specific proteins as novel biomarkers involved in the diagnosis and progression of gastric cancer[J]. Int J Mol Sci, 2023, 24(10):8833. |
| [2] |
SMYTH E C, NILSSON M, GRABSCH H I, et al. Gastric cancer[J]. Lancet, 2020, 396(10251):635-648.
doi: S0140-6736(20)31288-5 pmid: 32861308 |
| [3] | BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018 : GLOBOCAN estimates of incidence andmortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. |
| [4] | CHEN W, ZHENG R, BAADE P D, et al. Cancer statisticsin China,2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. |
| [5] | FENG R M, ZONG Y N, CAO S M, et al. Current cancer situation in China: good or bad news from the 2018 clobal cancer statistics?[J]. Cancer Commun(Lond), 2019, 39(1):22. |
| [6] | MATSUOKA T, YASHIRO M. Biomarkers of gastric cancer: current topics and future perspective[J]. World J Gastroenterol, 2018, 24(26):2818-2832. |
| [7] | ALIX-PANABIÈRES C, PANTEL K. Liquid biopsy: from discovery to clinical application[J]. Cancer Discov, 2021, 11(4):858-873. |
| [8] | YU L, XU Y, YANG J R, et al. miR-497 inhibits the growth and metastasis of SGC-7901 human gastric cancer anoikis resistant cells via blocking Wnt/β-catenin signaling pathway[J]. Chin J Cell Mol Immunol, 2023, 39(7):617-625. |
| [9] |
ZHAN T, CHEN M, LIU W, et al. MiR-455-3p inhibits gastric cancer progression by repressing Wnt/β-catenin signaling through binding to ARMC8[J]. BMC Med Genomics, 2023, 16(1):155.
doi: 10.1186/s12920-023-01583-y pmid: 37400847 |
| [10] | BARGIELA-IPARRAGUIRRE J, HERRERO J M, PAJUELO-LOZANO N, et al. Regulatory effects of miR-19a on MAD2 expression and tumorigenesis in gastric cancer[J]. Genes Dis, 2023, 10(4):1180-1182. |
| [11] | DARANG E, PEZESHKIAN Z, MIRHOSEINI S Z, et al. Bioinformatics and pathway enrichment analysis identified hub genes and potential biomarker for gastric cancer prognosis[J]. Front Oncol, 2023,13:1187521. |
| [12] | KNYAZEV E N, SAMATOV T R, FOMICHEVA K A, et al. MicroRNA hsa-miR-4674 in hemolysis-free blood plasma is associated with distant metastases of prostatic cancer[J]. Bull Exp Biol Med, 2016, 161(1):112-115. |
| [13] | LIAO Q, WANG Z, CADENA S M S C. Editorial: targe-ting oxidative stress in cancer: what is new in the prevention, diagnostic, treatment and prognostic strategies?[J]. Front Pharmacol, 2023,14:1229785. |
| [14] | AZADI S, TORKASHVAND E, MOHAMMADI E, et al. Analysis of EMT induction in a non-invasive breast cancer cell line by mesenchymal stem cell supernatant: study of 2D and 3D microfluidic based aggregate formation and migration ability, and cytoskeleton remodeling[J]. Life Sci, 2023,320:121545. |
| [15] | WARDAS B, SCHNEIDER J G, KLUGBAUER N, et al. Englerin A inhibits T-type voltage-gated calcium channels at low-micromolar concentrations[J]. Mol Pharmacol, 2023, 104(4):144-153. |
| [16] | GUPTA J, JALIL A T, ABD ALZAHRAA Z H, et al. The metformin immunoregulatory actions in tumor suppression and normal tissues protection[J]. Curr Med Chem, 2024, 31(33):5370-5396. |
| [1] | 朱正纲, 北山丈二, 金炯浩, 苏博仁, 曹晖, 陈凛, 程向东, 胡建昆, 今野元博, 石神浩德, 池艺燮, 金钟汉, 小寺泰弘, 梁寒, 刘晓文, 陆晟, 牟一平, 聂明明, 徐元俊, 王亚农, 吴丹, 徐则宽, 山口博纪, 严超, 杨中印, 印慨, 米村豊, 杨伟鹏, 于吉人, 张俊, 亚洲胃癌NIPS治疗协作组, 上海市抗癌协会腹膜肿瘤专业委员会. 腹腔内常温与全身联合治疗胃癌腹膜转移的亚洲专家共识[J]. 外科理论与实践, 2025, 30(04): 277-294. |
| [2] | 邹天慧. 2025年《美国胃肠病学会临床指南:胃癌前病变诊治指南》解读[J]. 诊断学理论与实践, 2025, 24(04): 393-400. |
| [3] | 华子辰, 梅郁, 李琛, 严超, 燕敏, 朱正纲, 姚学新. 胃癌病人大网膜转移率的初步探索(Dragon 05临床预试验)[J]. 外科理论与实践, 2025, 30(01): 41-46. |
| [4] | 汪逸舟, 韦琪, 金惠敏, 陈磊, 梁海滨, 周韵澜. 循环肿瘤细胞在进展期胃癌中的临床应用[J]. 外科理论与实践, 2024, 29(06): 549-554. |
| [5] | 褚玉丹, 孙海东, 崔冉, 郑鸿. 双硫死亡相关LncRNA在胃癌中的表达及其临床意义[J]. 外科理论与实践, 2024, 29(05): 414-425. |
| [6] | 陈长强, 严晓伟, 胡皆乐, 包皙婷, 项明, 姜松耀. 血清中PD-L1含量与胃癌病人预后的关系[J]. 外科理论与实践, 2024, 29(03): 230-235. |
| [7] | 龚婷婷, 钱爱华, 陈希. 个体化预测早期胃癌内镜黏膜下剥离术后迟发性出血风险的列线图模型构建[J]. 外科理论与实践, 2024, 29(03): 236-242. |
| [8] | 徐珊, 徐超. 老年胃癌整体评估及系统治疗现状[J]. 内科理论与实践, 2024, 19(03): 193-196. |
| [9] | 朱正纲. 联合抗血管生成、免疫检查点抑制剂与化疗在局部进展期胃癌新辅助治疗中的临床意义[J]. 外科理论与实践, 2024, 29(02): 132-137. |
| [10] | 吴熊焰, 李臻, 俞振佳, 苏丽萍. 假基因FMO6P抑制胃癌侵袭转移作用及其机制探索[J]. 外科理论与实践, 2024, 29(02): 161-169. |
| [11] | 于素悦, 陆爱国. 保留幽门的胃切除术在早期胃癌外科治疗中的应用及相关指南共识解读[J]. 外科理论与实践, 2024, 29(01): 81-86. |
| [12] | 张培婵, 罗春阳, 吴文雅, 吴震峰, 曹勤洪, 陈彻, 吴晓宇, 姚学权, 刘福坤. 基于倾向评分匹配法评估进展期胃癌合并同时性原发食管癌综合治疗的临床疗效[J]. 外科理论与实践, 2023, 28(06): 551-555. |
| [13] | 严超, 陆晟, 燕敏, 朱正纲. 《日本胃癌治疗指南2021(第6版)》解读及瑞金实践[J]. 外科理论与实践, 2023, 28(04): 326-354. |
| [14] | 孙祺, 黄文博, 何炳良, 刘畅, 徐宇航, 赵伟. 预防性腹腔热灌注化疗对局部进展期胃癌根治术后病人预后改善的有效性研究[J]. 外科理论与实践, 2023, 28(04): 366-370. |
| [15] | 孙强, 姚骏, 张鑫, 杜杉珊, 王伟军. 近端胃切除抗反流消化道重建方式的研究进展[J]. 外科理论与实践, 2023, 28(04): 388-393. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||